Page 235 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 235
Optimal timing and response criteria of Interim-PET in DLBCL
References
1. Zinzani PL, Gandolfi L, Broccoli A, et al: Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer. 117:1010-1018, 2011.
2. Mikhaeel NG, Smith D, Dunn JT, et al: Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 43:1209-1219, 2016.
3. Lugtenburg PJ, de Nully Brown P, van der Holt B, et al: Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. JCO1903418, 2020.
4. Carr R, Fanti S, Paez D, et al: Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 55:1936-1944, 2014.
5. Mikhaeel NG, Cunningham D, Counsell N, et al: FDG-PET/CT after two cycles of RCHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2020.
6. Mylam KJ, Kostakoglu L, Hutchings M, et al: (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma. 56:2005-2012, 2015.
7. Duhrsen U, Muller S, Hertenstein B, et al: Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 36:2024-2034, 2018.
8. Mamot C, Klingbiel D, Hitz F, et al: Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol. 33:2523-2529, 2015.
233
8
